| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/24/2006 | US6989386 Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same |
| 01/24/2006 | US6989385 Pyrazole compounds useful as protein kinase inhibitors |
| 01/24/2006 | US6989372 medicaments intended to increase the intracellular and/or extracellular level of glutathione (GSH); for example, N-(N-Acetyl-L-cysteinyl)-S-acetylcysteamine; hiv treatment |
| 01/24/2006 | US6989262 Plasmin variants and uses thereof |
| 01/24/2006 | US6989260 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders |
| 01/24/2006 | US6989159 Pharmaceutical compositions containing lithium carbonate |
| 01/24/2006 | US6989156 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated |
| 01/24/2006 | US6989146 Stress proteins and peptides and methods of use thereof |
| 01/24/2006 | US6989143 Depletion method of blood plasma ascorbate |
| 01/24/2006 | CA2327325C Stimulus sensitive gel with radioisotope and methods of making |
| 01/24/2006 | CA2209775C Analogues of n-acetylardeemin, method of preparation and uses thereof |
| 01/24/2006 | CA2100228C Phospholipid derivatives |
| 01/19/2006 | WO2006007491A1 Mitotic kinesin inhibitors |
| 01/19/2006 | WO2006007398A1 Therapy of platinum-resistant cancer |
| 01/19/2006 | WO2006006720A1 METHOD OF CULTURING ϜδT CELLS, ϜδT CELLS AND REMEDY/PREVENTIVE |
| 01/19/2006 | WO2006006693A1 Anti-glypican 3 antibody |
| 01/19/2006 | WO2006006638A1 DENDRITIC CELL, DRUG CONTAINING THE DENDRITIC CELL, THERAPEUTIC METHOD USING THE DENDRITIC CELL AND METHOD OF CULTURING ϜδT CELL |
| 01/19/2006 | WO2006005955A1 Amide derivatives as inhibitors of histone deacetylase |
| 01/19/2006 | WO2006005856A1 Use of polyphenol ethylene organometallic derivatives for treating a non-hormone dependent cancer |
| 01/19/2006 | WO2006005759A2 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 01/19/2006 | WO2006005268A2 Pharmaceutical composition containing polypeptide fragments of serralysins |
| 01/19/2006 | WO2005117890A3 Thienopyrimidines and thiazolopyrimidines for use in medicine |
| 01/19/2006 | WO2005105805A9 Annelated carbamoylase-heterocycles, focused library, pharmaceutical compositions and methods for the production thereof |
| 01/19/2006 | US20060014930 Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
| 01/19/2006 | US20060014830 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS |
| 01/19/2006 | US20060014811 Medicament for treatment of cancer |
| 01/19/2006 | US20060014804 Cyanoguanidine prodrugs |
| 01/19/2006 | US20060014803 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics |
| 01/19/2006 | US20060014796 Epothilone derivatives |
| 01/19/2006 | US20060014794 CXCR1 and CXCR2 chemokine antagonists |
| 01/19/2006 | US20060014787 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 01/19/2006 | US20060014780 Nicotinamide derivatives useful as PDE4 inhibitors |
| 01/19/2006 | US20060014762 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives |
| 01/19/2006 | US20060014755 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/19/2006 | US20060014747 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents |
| 01/19/2006 | US20060014742 Amide derivative |
| 01/19/2006 | US20060014741 Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| 01/19/2006 | US20060014736 Phenothiazine kinesin inhibitors |
| 01/19/2006 | US20060014730 Ansamycin formulations and methods for producing and using same |
| 01/19/2006 | US20060014725 6-(1-benzyl-3-pentyl-1H-indol-2-yl)-1-bromo-2-naphthyl 1H-tetraazol-5-ylmethyl ether; useful in treating stroke associated with or resulting from atrial fibrillation; thrombolytic agents for prohylaxis of cardiovascular disorders |
| 01/19/2006 | US20060014718 oversulfation of epiK-N sulfate to obtain an epiK5-amine-O-oversulfate with very high sulfation degree which by subsequent N-sulfation provides new epiK5-N,O-oversulfate-derivatives; free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field |
| 01/19/2006 | US20060014701 Novel amide derivatives as growth hormone secretagogues |
| 01/19/2006 | US20060014693 Peptide inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) activity |
| 01/19/2006 | US20060014688 Methods of inhibiting tumor cell proliferation |
| 01/19/2006 | US20060014672 Tumor specific oligosaccharide epitopes and use thereof |
| 01/19/2006 | US20060014243 Human G-protein chemokine receptor HSATU68 |
| 01/19/2006 | US20060014222 Antibodies |
| 01/19/2006 | US20060014180 Human phosphatase RET31, and variants thereof |
| 01/19/2006 | US20060013902 Pharmaceutical products for treating neoplastic disease and inflammation |
| 01/19/2006 | US20060013897 Compositions for cancer therapy saponins or sapogenins |
| 01/19/2006 | US20060013883 Poloxamer and poloxamine compositions for nucleic acid delivery |
| 01/19/2006 | US20060013869 Electrospun amorphous pharmaceutical compositions |
| 01/19/2006 | US20060013860 Anticancer agents; side effect reduction |
| 01/19/2006 | US20060013852 Use of organic compounds |
| 01/19/2006 | US20060013836 Dissolving ixabepilone in tert-butanol and water, and then vacuum drying to lypophilize; 7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-7-oxabicyclo[14.1.0]heptadecane-5,9-dione is ixabepilone |
| 01/19/2006 | US20060013817 identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. |
| 01/19/2006 | US20060013801 Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity |
| 01/19/2006 | DE60110592T2 Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer A pharmaceutical composition comprising a farnesyl transferase inhibitory 1,2-annelated quinoline enantiomer |
| 01/19/2006 | DE102004031656A1 Tetrahydrochinoline Tetrahydroquinolines |
| 01/19/2006 | CA2573609A1 Porphyrin derivatives and their use in photon activation therapy |
| 01/19/2006 | CA2573596A1 S100 protein inhibitors for treating leukemia |
| 01/19/2006 | CA2573456A1 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 01/19/2006 | CA2573380A1 Amide derivatives as inhibitors of histone deacetylase |
| 01/19/2006 | CA2573372A1 Sulfonamide derivatives |
| 01/19/2006 | CA2573176A1 Nup98-hox fusions for expansion of hemopoietic stem cells |
| 01/19/2006 | CA2573092A1 Pyridodihydropyrazinones method for production and use thereof as medicaments |
| 01/19/2006 | CA2573072A1 Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
| 01/19/2006 | CA2572984A1 A pharmaceutical composition containing polypeptide fragments of the serralysins |
| 01/19/2006 | CA2571807A1 Mitotic kinesin inhibitors |
| 01/19/2006 | CA2571756A1 2, 4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 01/19/2006 | CA2571750A1 2, 4, 6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 01/19/2006 | CA2571748A1 2, 4, 6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 01/19/2006 | CA2571739A1 A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin |
| 01/19/2006 | CA2568526A1 Combination therapy with radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma |
| 01/19/2006 | CA2567808A1 Therapy of platinum-resistant cancer |
| 01/19/2006 | CA2561841A1 Methods for suppressing neovascularization using ephrinb2 |
| 01/19/2006 | CA2553436A1 Peptides selectively lethal to malignant and transformed mammalian cells |
| 01/19/2006 | CA2544692A1 Anti-glypican 3 antibody |
| 01/18/2006 | WO2007026190A2 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| 01/18/2006 | EP1617218A1 METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY |
| 01/18/2006 | EP1617216A1 Novel method of screening |
| 01/18/2006 | EP1616957A1 Vector |
| 01/18/2006 | EP1616956A1 Cell death-inducing fused gene acting specifically on cancer and gene product thereof |
| 01/18/2006 | EP1616954A2 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 01/18/2006 | EP1616950A1 Peptide having htlv-1-specific ctl-inducing activity |
| 01/18/2006 | EP1616948A1 Thioredoxin modification |
| 01/18/2006 | EP1616883A2 Antibodies against VLA-4 |
| 01/18/2006 | EP1616882A2 Apo-2 receptor antibodies |
| 01/18/2006 | EP1616878A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/18/2006 | EP1616875A1 GD3-mimetic peptides |
| 01/18/2006 | EP1616874A1 Mono- and bicyclic compounds with therapeutic activity and pharmaceutical compositions including them |
| 01/18/2006 | EP1616873A1 Lipid-regulating agent and use thereof |
| 01/18/2006 | EP1616871A1 Porphyrin compound containing biotinyl group and use thereof |
| 01/18/2006 | EP1616862A1 Nitrogenous heterocyclic compound and use thereof |
| 01/18/2006 | EP1616856A1 Novel transcriptional factor, process for producing the same and use thereof |
| 01/18/2006 | EP1616579A1 CD40 binding molecules and CTL peptides for treating tumors |
| 01/18/2006 | EP1616578A1 Compositions and methods for delivery of genetic material |
| 01/18/2006 | EP1616575A1 Method for treating inflammation |
| 01/18/2006 | EP1616572A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
| 01/18/2006 | EP1616564A2 Manipulation of nitrosative stress for treating microbes and helminths |